KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Common Equity (2016 - 2025)

NovoCure's Common Equity history spans 12 years, with the latest figure at $340.5 million for Q4 2025.

  • For Q4 2025, Common Equity fell 5.47% year-over-year to $340.5 million; the TTM value through Dec 2025 reached $340.5 million, down 5.47%, while the annual FY2025 figure was $340.5 million, 5.47% down from the prior year.
  • Common Equity for Q4 2025 was $340.5 million at NovoCure, roughly flat from $341.3 million in the prior quarter.
  • Across five years, Common Equity topped out at $445.4 million in Q3 2022 and bottomed at $340.5 million in Q4 2025.
  • The 5-year median for Common Equity is $382.9 million (2021), against an average of $389.8 million.
  • The largest annual shift saw Common Equity soared 53.81% in 2021 before it fell 17.83% in 2023.
  • A 5-year view of Common Equity shows it stood at $410.5 million in 2021, then grew by 7.47% to $441.2 million in 2022, then fell by 17.83% to $362.5 million in 2023, then decreased by 0.64% to $360.2 million in 2024, then dropped by 5.47% to $340.5 million in 2025.
  • Per Business Quant, the three most recent readings for NVCR's Common Equity are $340.5 million (Q4 2025), $341.3 million (Q3 2025), and $349.4 million (Q2 2025).